Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhengyang, Wu, Guocong, Zhang, Xiao, Gao, Jiale, Meng, Cong, Liu, Yishan, Wei, Qi, Sun, Liting, Wei, Pengyu, Bai, Zhigang, Yao, Hongwei, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501688/
https://www.ncbi.nlm.nih.gov/pubmed/36159842
http://dx.doi.org/10.3389/fimmu.2022.1001444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501688/
https://www.ncbi.nlm.nih.gov/pubmed/36159842
http://dx.doi.org/10.3389/fimmu.2022.1001444

Ejemplares similares